Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study

BACKGROUND: Monoclonal antibodies (mAbs) against calcitonin gene-related peptides (CGRP) are novel treatments for migraine prevention. Based on a previous functional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) the CGRP ligand mAb galcanezumab would alt...

Descripción completa

Detalles Bibliográficos
Autores principales: Basedau, Hauke, Sturm, Lisa-Marie, Mehnert, Jan, Peng, Kuan-Po, Schellong, Marlene, May, Arne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126581/
https://www.ncbi.nlm.nih.gov/pubmed/35604755
http://dx.doi.org/10.7554/eLife.77146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126581/
https://www.ncbi.nlm.nih.gov/pubmed/35604755
http://dx.doi.org/10.7554/eLife.77146

Ejemplares similares